News - MabThera, Norgine

Filter

Current filters:

MabTheraNorgine

Popular Filters

1 to 25 of 27 results

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

24-01-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today approved the use…

EuropeImmunologicalsMabTheraPharmaceuticalPricingRegulationRocheUK

Norgine and Kissei’s Savene approved in Japan

21-01-2014

Independent Dutch firm Norgine and its Japanese partner Kissei Pharmaceutical received approval from…

Asia-PacificKissei PharmaceuticalNorgineOncologyPharmaceuticalRegulationSavene

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

07-11-2013

Swiss drug major Roche (ROG: SIX) has announced new data from the second stage of the CLL11 Phase III…

EuropeGazyvaMabTheraOncologyPharmaceuticalResearchRituxanRoche

Roche’s Gazyva gains FDA approval of CLL

Roche’s Gazyva gains FDA approval of CLL

04-11-2013

The US Food and Drug Administration late Friday approved Roche’s Gazyva (obinutuzumab), also known…

Biogen IdecBiotechnologyGazyvaGenentechMabTheraNorth AmericaobinutuzumabOncologyRegulationRituxanRoche

UK’s NICE thumbs up for Roche drug in rare autoimmune disease in draft guidance

UK’s NICE thumbs up for Roche drug in rare autoimmune disease in draft guidance

03-10-2013

The UK’s drugs watchdog, the National Institute for Health and Care Excellence (NICE) has published…

EuropeMabTheraOncologyPharmaceuticalPricingRegulationRoche

Biocad enters deal for exporting rituximab biosimilar to Turkey

22-08-2013

Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

Study finds Norgine's Dantrium reduces fatal anesthetic reactions

19-08-2013

A new epidemiologic study has found that Dantrium (dantrolene sodium) is effective in reducing fatal…

NorgineNorth AmericaPharmaceuticalResearch

UK's NICE calls for more data to consider Roche drug for a type of vasculitis

23-07-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published…

BiotechnologyEuropeMabTheraOncologyPharmaceuticalPricingRare diseasesRegulationRoche

New EULAR recommendations address use of synthetic and biological DMARDs

05-07-2013

The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Russia's Biocad plans to produce high-tech drugs in Brazil

19-03-2013

Biocad, one of Russia's leading biotechnology companies, plans to launch production of several of its…

AvastinBiocadBiotechnologyGenericsHerceptinMabTheraOncologyProductionRocheSouth America

Roche aims for expansion in Russia; Pharmsynthez production plans

20-02-2013

Swiss pharmaceutical major Roche (ROG: SIX) plans to accelerate its expansion into the Russian pharmaceutical…

EuropeMabTheraPharmaceuticalPharmsynthezProductionRoche

Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia

04-02-2013

Swiss drug major Roche (ROG: SIX) says that the first stage of a Phase III study with its investigational…

BiotechnologyGA101MabTheraobinutuzumabOncologyPharmaceuticalResearchRituxanRoche

Alfa Wassermann and Norgine's Targaxan gets first European launch, in UK

28-01-2013

Following recent European Union approval (The Pharma Letter December 9, 2012), Netherlands-based Norgine…

Alfa WassermannEuropeMarkets & MarketingNephrology and HepatologyNorginePharmaceuticalTargaxanXifaxan

Norgine and SpePharm set up JV to commercialize portfolio of drugs

18-12-2012

Independent Dutch firm Norgine BV and fellow Amsterdam-based SpePharm Holding BV have concluded a broad…

Markets & MarketingMergers & AcquisitionsNorginePharmaceuticalSpePharma

Alfa Wassermann and Norgine get EU approval for Xifaxan

09-12-2012

Italy-based Alfa Wassermann and Netherlands-headquartered Norgine say they have received European Marketing…

Alfa WassermannAntibiotics and Infectious diseasesEuropeNorginePharmaceuticalRegulationXifaxan

New Zealand's PHARMAC decisions on Roche products

11-10-2012

PHARMAC, the pharmaceutical management agency in New Zealand, has made decisions on the proposal for…

Asia-PacificAvastinHypnovelMabTheraPharmaceuticalPricingRegulationRocheValcyte

EMA confirms Roche's MabThera made at Vacaville site poses no health risk

28-05-2012

Following a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines…

Anti-Arthritics/RheumaticsBiotechnologyMabTheraOncologyPharmaceuticalRegulationRoche

Tranzyme and Norgine's ulimorelin fails to meet endpoints

27-05-2012

USA-based Tranzyme Pharma (Nasdaq: TZYN) and independent Dutch drugmaker Norgine have announced disappointing…

Gastro-intestinalsNorginePharmaceuticalResearchTranzymeTZP-102ulimorelin

Tranzyme and Norgine bowel cancer drug fails in Ph III

12-03-2012

USA-based Tranzyme Pharma (Nasdaq: TZYM) and independent drugmaker Norgine of the Netherlands yesterday…

NorgineOncologyPharmaceuticalResearchTranzymeulimorelin

Nycomed to market Norgine’s laxative MoviPrep in Russia and CIS

23-08-2011

Swiss independent drugmaker Nycomed and Netherlands-headquartered Norgine, have entered into a licensing…

EuropeGastro-intestinalsLicensingMarkets & MarketingMoviPrepNorgineNycomedPharmaceutical

1 to 25 of 27 results

Company Spotlight

Fibrotech

Fibrotech

Back to top